Human b-cells are functionally mature by the age of 1 year. The timeline and mechanisms of this maturation are unknown owing to the exceptional availability of testable tissue. Here, we report the first in vitro study of insulin secretion by islets from a 5-day-old newborn. Glucose was inefficient alone, but induced insulin secretion, which was concentration-dependent, showed a biphasic time-course and was of similar magnitude as in infant islets when b-cell cyclic adenosine monophosphate was raised by forskolin. Tolbutamide alone was effective in low glucose, but its effect was not augmented by high glucose. Metabolic amplification by glucose was thus inoperative, in contrast to amplification by cyclic adenosine monophosphate. Newborn islets showed high basal insulin secretion that could be inhibited by diazoxide or omission of CaCl 2 . Postnatal acquisition of functional maturity by human b-cells implicates control of basal secretion and production of metabolic signals able to activate both triggering and amplifying pathways of insulin secretion.
INTRODUCTION
In vitro studies have established that pancreatic b-cells are functionally immature, with virtually no response to glucose, in human fetuses between 12 and 22 weeks-of-gestation [1] [2] [3] [4] [5] . Using islets isolated from five infants, we recently showed that b-cells reach functional maturity by the age of 1 year 6 . Characterization of insulin secretion between birth and 1 year-of-age would thus be necessary to identify the timeline and mechanisms of human b-cell maturation, but such studies are very rare. Intravenous injection of glucose was found to increase plasma insulin levels in the umbilical vein of 1-7-day-old newborns 7 , but larger rises in insulin were observed during infusion of amino acids than glucose 8, 9 . In islet-like cell clusters from two neonates (aged 2 and 5 weeks) born at term, high glucose induced a small, rapid release of insulin with virtually no second phase, except when cyclic adenosine monophosphate (cAMP) was increased with theophylline 2 . In the present communication, we report the first study of insulin secretion in islets from a human newborn.
METHODS
Islets were isolated from the pancreas of a 5-day-old female donor referred to the transplantation unit of the Medical Faculty of the University of Louvain in Brussels, Belgium. Approval of the experimental use of the islets was granted by the ethics committee of our institution, and consent was given by the parents. Gestation was complicated by the mother's hypertension, and interrupted by placental abruption after 35 weeks. The newborn had a normal weight of 2.5 kg for gestational age, but did not survive owing to severe asphyxia. The pancreas was retrieved after 25 min of cardiac arrest. The procedure of islet isolation was similar to that reported for adult or infant islets 6, 10 . We received 2,400 islets with a purity of 25% (owing to only partial purification) and 87% viability. After culture for 37 h in RPMI medium containing 10% heatinactivated fetal calf serum and 5 mmol/L glucose, similar portions of the preparation were perifused with a bicarbonatebuffered salt-balanced solution 10 supplemented with glucose and other test agents. In many experiments 1 lmol/L forskolin was used to increase b-cell cAMP. At the end of experiments, islets were recovered from perifusion chambers and insulin was extracted in acid ethanol 11 . Insulin was measured in effluent fractions collected every 2 min and in extracts. Fractional insulin secretion rates were then calculated as the percentage of insulin content secreted per minute, which is independent of differences in islet number between experiments 11 .
RESULTS
The insulin content of newborn islets (4.1 ng/islet) was much lower than that of infant islets (13.8 ng/islet, range 9.8-18.9 ng/ islet) 6 . During perifusion without forskolin, switching from zero to 1 mmol/L glucose (G0 to G1) caused a tiny increase in insulin secretion, but further stepwise increases in glucose were ineffective, whereas returning from G10 to G1 induced a paradoxical off-response ( Figure 1a , open circles). Similar, mechanistically unexplained, off-responses have been observed in strongly stimulated islets from infants and adults 6, 10, 11 . In the presence of forskolin, glucose induced a clear concentration-dependent stimulation of insulin secretion that reached 3.7-fold in G10 (Figure 1a , filled circles). The responses in newborn islets differ from those previously measured in infant islets 6 in two respects: (i) the stimulatory effect of glucose requires elevation of b-cell cAMP by forskolin; and (ii) basal insulin secretion (in G0-G1) is markedly elevated in islets from the newborn (Figure 1b,c) .
Switching from G1 to G15 induced a rapid but small (threefold) peak of insulin secretion, followed by a return to similar values as in G1 (Figure 1d , open circles). Opening adenosine triphosphate-sensitive potassium channels with diazoxide inhibited insulin secretion to values fourfold lower than baseline in G1 alone. Subsequent closure of the channels with tolbutamide not only reversed the inhibition, but doubled the secretion rate compared with G15 alone (Figure 1d ). These changes of small amplitude were considerably amplified by the presence of forskolin during the whole experiment (Figure 1d, filled circles) . The dynamics of glucose-induced insulin secretion and of the responses to diazoxide and tolbutamide were the same as in infant islets 6 , but the amplitude of the changes was smaller in the absence of forskolin (Figure 1e ) and similar in its presence (Figure 1f) .
The addition of a mixture of leucine and glutamine to a medium containing G3 and forskolin induced biphasic insulin secretion, which was reversibly abolished by omission of CaCl 2 from the medium (Figure 1g ). The dynamics of the changes were the same as in infant islets 6 , but, again, the fold-change was smaller owing to the higher basal secretion rate in newborn islets. In G1 alone, tolbutamide rapidly stimulated insulin secretion in islets from the neonate, but a subsequent increase in glucose was inefficient (Figure 1h ) in contrast to the amplification observed in infant islets 6 . Returning to G1 was followed by a paradoxical off-response, and the final addition of forskolin amplified secretion.
Finally, a pulse of high extracellular CaCl 2 strongly and reversibly stimulated insulin secretion in islets from the newborn, both in the absence and presence of forskolin (Figure 1i ). This efficiency of high extracellular CaCl 2 is in complete agreement with in vivo observations in 3-day-old newborns 12 .
DISCUSSION
We previously reported that islets from 11-36-month-old infants secrete insulin virtually like adult islets in vitro 6 . The only significant difference was that infant islets secreted a lower proportion of their insulin stores under both basal and stimulated conditions 6 . Without cAMP, glucose hardly induced insulin secretion in islet cell clusters from two neonates aged 2 and 5 weeks 2 . The present, more extensive characterization of insulin secretion by intact islets from one full-term newborn is unprecedented. We believe that the rarity of the information outweighs the limitations inherent to the use of a single preparation.
A major difference with infant islets 6 was that newborn bcells required cAMP to become glucose-competent. Whereas glucose alone only slightly and transiently increased insulin secretion, glucose stimulation was concentration-dependent, showed a biphasic time-course (with a slowly declining second phase) and was of similar magnitude as in infant islets when forskolin was used to increase b-cell cAMP. The triggering action of glucose is thus immature and requires simultaneous elevation of cAMP to be detected, just as in fetal b-cells 2, 3 . In contrast, tolbutamide and high extracellular CaCl 2 were effective without forskolin. This indicates that the triggering signal (cytosolic Ca
2+
) is operative on exocytosis, and indirectly suggests that the inefficiency of glucose alone is due to its inability of increasing Ca 2+ in b-cells, as in fetal islet cell clusters 5 . In adult human b-cells, glucose promotes cAMP formation 13 , and hormones or drugs, that increase cAMP, potentiate the elevation of cytosolic Ca 2+ by facilitating closure of adenosine triphosphate-sensitive potassium channels 14 and opening of voltagegated calcium channels 15 , and by improving coordination of Ca 2+ changes between b-cells 16 . Too few newborn islets were available for mechanistic studies, but we speculate that cAMP production is insufficient.
Another important difference between newborn and infant or adult islets 6, 10 was that tolbutamide-induced insulin secretion was not augmented by high glucose in newborn islets. This shows that metabolic amplification of the exocytotic response to cytosolic Ca 2+ is not operative, in contrast to amplification by cAMP. A last feature of newborn islets was a high basal rate of insulin secretion, which does not reflect mere uncontrolled leak of insulin, because it was augmented by forskolin and inhibited by diazoxide or omission of extracellular CaCl 2 .
Postnatal maturation of murine b-cells involves epigenetic silencing of genes coding for some metabolic enzymes, such as hexokinase-I 17 . However, accelerated metabolism at low glucose concentrations could not entirely explain elevation of basal secretion, which was also present in the absence of glucose. In addition, glucokinase is expressed well before term in human b-cells 4 , and the concentration-dependent effects of glucose in the presence of forskolin indirectly suggest functioning of the enzyme.
In conclusion, b-cells from this single neonate were functionally immature compared with b-cells from young infants 6 . Our observations suggest that the transition occurring during the first year of life implicates control of basal secretion and changes in the production of metabolic signals able to activate both triggering and amplifying pathways of insulin secretion. Whereas lowering of the baseline is unlikely to depend on cAMP production, maturation of cAMP signaling is probably important for full actuation of the two pathways involved in glucose stimulation. 
